Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.

Schmeling, Heinrike

Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. [electronic resource] - Arthritis & rheumatology (Hoboken, N.J.) Sep 2014 - 2580-9 p. digital

Publication Type: Journal Article

2326-5205

10.1002/art.38741 doi


Adalimumab
Adolescent
Antibodies, Monoclonal, Humanized--adverse effects
Antirheumatic Agents--adverse effects
Arthritis, Juvenile--drug therapy
Biological Products--adverse effects
Child
Female
Germany
Humans
Male
Registries
Severity of Illness Index
Treatment Outcome